Epigenetics in Drug Discovery

Chromatrap®, a business unit of Porvair Sciences, has announced that it will be the Lead Sponsor at the prestigious “Epigenetics in Drug Discovery” conference to be held in Cambridge, UK from 26th-27th January 2016.

porvairpr438-image

Viewed as a new frontier in drug discovery, rapid progress has been made in enhancing understanding of epigenetic mechanisms of both new and existing drugs. With the processes that control epigenomic function providing new opportunities, epigenetics targets are enabling the discovery of novel drugs.

At the conference - Dr Amy Beynon will deliver a presentation highlighting the use of new Chromatrap solid state ChIP technology for assaying methylated and hydroxymethylated DNA marks in addition to Histone modifications and the use of Chromatrap kits for ChIP-sequencing.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Chromatrap® - Porvair Sciences Ltd. (2019, June 19). Epigenetics in Drug Discovery. News-Medical. Retrieved on November 24, 2020 from https://www.news-medical.net/news/20160105/Epigenetics-in-Drug-Discovery.aspx.

  • MLA

    Chromatrap® - Porvair Sciences Ltd. "Epigenetics in Drug Discovery". News-Medical. 24 November 2020. <https://www.news-medical.net/news/20160105/Epigenetics-in-Drug-Discovery.aspx>.

  • Chicago

    Chromatrap® - Porvair Sciences Ltd. "Epigenetics in Drug Discovery". News-Medical. https://www.news-medical.net/news/20160105/Epigenetics-in-Drug-Discovery.aspx. (accessed November 24, 2020).

  • Harvard

    Chromatrap® - Porvair Sciences Ltd. 2019. Epigenetics in Drug Discovery. News-Medical, viewed 24 November 2020, https://www.news-medical.net/news/20160105/Epigenetics-in-Drug-Discovery.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
First commercial ChIP kit range released for Drosophila